Lixte Biotechnology Enters Material Definitive Agreement
Ticker: LIXT · Form: 8-K · Filed: Dec 2, 2024 · CIK: 1335105
| Field | Detail |
|---|---|
| Company | Lixte Biotechnology Holdings, INC. (LIXT) |
| Form Type | 8-K |
| Filed Date | Dec 2, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement
Related Tickers: LIXT
TL;DR
LIXT signed a big deal on Nov 29th. Details TBD.
AI Summary
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on November 29, 2024. The filing does not specify the nature of the agreement or any associated dollar amounts, but it indicates a significant event for the company.
Why It Matters
This filing signals a significant development in Lixte Biotechnology's operations, potentially impacting its future business strategies and financial standing.
Risk Assessment
Risk Level: medium — The filing indicates a material definitive agreement, which could carry significant implications, but lacks specific details, creating uncertainty.
Key Players & Entities
- LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — Filer
- November 29, 2024 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Lixte Biotechnology Holdings, Inc.?
The filing does not specify the nature of the material definitive agreement.
When was the material definitive agreement entered into?
The material definitive agreement was entered into on November 29, 2024.
What is the principal executive office address for Lixte Biotechnology Holdings, Inc.?
The principal executive office address is 680 East Colorado Blvd., Suite 180, Pasadena, California 91101.
What is the telephone number for Lixte Biotechnology Holdings, Inc.?
The telephone number is (631) 830-7092.
What is the SIC code for Lixte Biotechnology Holdings, Inc.?
The Standard Industrial Classification (SIC) code is 2834, Pharmaceutical Preparations.
Filing Stats: 586 words · 2 min read · ~2 pages · Grade level 13.5 · Accepted 2024-12-02 16:05:26
Filing Documents
- form8-k.htm (8-K) — 42KB
- ex10-1.htm (EX-10.1) — 4KB
- ex10-1_001.jpg (GRAPHIC) — 437KB
- ex10-1_002.jpg (GRAPHIC) — 275KB
- ex10-1_003.jpg (GRAPHIC) — 131KB
- ex10-1_004.jpg (GRAPHIC) — 331KB
- ex10-1_005.jpg (GRAPHIC) — 28KB
- 0001493152-24-048292.txt ( ) — 1919KB
- lixt-20241129.xsd (EX-101.SCH) — 3KB
- lixt-20241129_def.xml (EX-101.DEF) — 29KB
- lixt-20241129_lab.xml (EX-101.LAB) — 36KB
- lixt-20241129_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 2, 2024 LIXTE BIOTECHNOLOGY HOLDINGS, INC. By: /s/ BASTIAAN VAN DER BAAN Bastiaan van der Baan, President and Chief Executive Officer INDEX TO EXHIBITS Exhibit No. Description 10.1 Amendment 3 to Development Collaboration Agreement 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)